VACCINEX, INC.

Vaccinex, Inc. is a clinical-stage biotechnology company that discovers and develops targeted biotherapies to address serious conditions with unmet medical needs, particularly neurodegenerative diseases, cancer, and autoimmune disorders. The company's lead product candidate is pepinemab, an antibody designed to block semaphorin 4D signaling for the treatment of Alzheimer's disease as well as head and neck, pancreatic, and breast cancers. In addition, Vaccinex utilizes its proprietary ActivMAb human antibody discovery platform to generate monoclonal antibodies targeting complex multipass membrane proteins, yielding candidates such as VX5 for autoimmune indications. The company collaborates with third-party researchers and pharmaceutical partners who evaluate its pipeline candidates in clinical trials or use its discovery platform under licensing and research agreements.

The company conducts its operations in the United States and maintains its corporate headquarters and principal executive offices in Rochester, New York. Its business activities primarily involve clinical trials and research collaborations conducted across domestic locations.

Summary of the business section of Vaccinex's latest annual report, written by StockData.

“As of December 31, 2024, we had 23 full-time employees and 4 part-time employees.”